Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Holocene Advisors LP

Holocene Advisors LP reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 55.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 93,365 shares of the medical equipment provider's stock after selling 115,704 shares during the quarter. Holocene Advisors LP's holdings in Zimmer Biomet were worth $10,079,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. American Century Companies Inc. raised its position in shares of Zimmer Biomet by 12.6% in the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock valued at $391,239,000 after purchasing an additional 411,163 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Zimmer Biomet by 6.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock valued at $365,163,000 after purchasing an additional 211,637 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Zimmer Biomet by 0.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider's stock valued at $277,357,000 after purchasing an additional 9,990 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Zimmer Biomet by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider's stock valued at $196,523,000 after acquiring an additional 154,447 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Down 0.1 %

ZBH traded down $0.13 on Wednesday, hitting $110.61. The company had a trading volume of 1,438,157 shares, compared to its average volume of 1,493,587. The firm has a market cap of $22.02 billion, a P/E ratio of 21.03, a PEG ratio of 2.03 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The company's fifty day moving average price is $107.49 and its 200 day moving average price is $109.16. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet's revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.65 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Analysts Set New Price Targets

ZBH has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Raymond James dropped their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. BTIG Research dropped their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research note on Thursday, October 3rd. Robert W. Baird dropped their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI lowered their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.